Nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with Pompe disease (acid ?-glucosidase deficiency).
MeSH: Glycogen Storage Disease Type II
Group: Other alimentary tract and metabolism products